The development of new therapeutic approaches is a central focus of modern cancer research, particularly for tumor diseases that are difficult to treat. We are therefore concentrating on the development of innovative antibody therapies to improve the treatment options for difficult-to-treat tumors. These tumours are characterized by low immune cell infiltration and high resistance to existing therapies and therefore represent a particularly great scientific challenge.
In a recently launched EUREKA project as part of the EU's EUROSTARS program, which is supported nationally by the German Federal Ministry of Education and Research and the German Aerospace Center (DLR), we are working on a new innovative approach for such a therapy in cooperation with the Ludwig Maximilian University of Munich and the Danish companies Cymab ApS and Bioneer A/S. To this end, strategies are being implemented that enable targeted activation of the immune system in tumor tissue to create the basis for more effective treatment options. Preclinical studies, which are carried out both in vitro and in vivo, serve to gain important insights for the further development of highly innovative antibodies. Thanks to our extensive expertise in conducting preclinical trials, we act as a reliable cooperation partner in the project.
We expect the results of this project to represent an important milestone in the development of innovative therapeutic strategies for difficult-to-treat tumors. These advances would not only strengthen our understanding of this type of tumor disease, but also significantly expand our range of services. With the newly acquired expertise, we can offer our customers tailored preclinical tumor models and approaches at the highest scientific level to jointly develop pioneering therapies.